Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793625 | 0.92 | IDO1 (0.39) | NPSR1IDO1SIGMAR1DRD2MAPT | |
| SCHEMBL6795334 | 0.76 | CCNA2 (0.40) | SIGMAR1DRD2GAAMEN1KMT2A | |
| SCHEMBL6787051 | 0.73 | DRD2 (0.42) | IDO1SIGMAR1DRD2 | |
| SCHEMBL6794639 | 0.72 | HCAR2 (0.42) | SIGMAR1DRD2 | |
| SCHEMBL5228886 | 0.71 | CCNA2 (0.38) | NPSR1SIGMAR1DRD2MAPT | |
| SCHEMBL6799794 | 0.71 | DRD2 (0.40) | SIGMAR1DRD2 | |
| SCHEMBL6787671 | 0.69 | CCNA2 (0.45) | DRD2 | |
| SCHEMBL6793109 | 0.69 | STK17B (0.38) | SIGMAR1DRD2 | |
| SCHEMBL31357648 | 0.68 | BCHE (0.46) | SIGMAR1DRD2GAAMEN1KMT2A | |
| SCHEMBL6792702 | 0.68 | DRD2 (0.42) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | NPSR1 2809/4885IDO1 2548/4885SIGMAR1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.